Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100868
B. Ma, K. Hu, R. Karatill, R. Williams, J. Hayre, S. Srivastava, S. Cordoba, S. Onuoha
{"title":"57P SENDER™ directed LNP delivery of mRNA for in situ generation of highly potent CAR T cells","authors":"B. Ma, K. Hu, R. Karatill, R. Williams, J. Hayre, S. Srivastava, S. Cordoba, S. Onuoha","doi":"10.1016/j.iotech.2024.100868","DOIUrl":"10.1016/j.iotech.2024.100868","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100868"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143134576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100837
D. Ziogas , H. Linardou , A. Charpidou , A. Koumarianou , G. Mountzios , P. Kosmidis , C. Christodoulou , D. Mavroudis , A.N. Christopoulou , I. Korantzis , S. Baka , M. Vaslamatzis , I. Athanasiadis , A. Koutras , D. Mauri , A. Kotsakis , A. Visvikis , F. Spanoudi , T. Tsichritzis , K. Syrigos
{"title":"94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study","authors":"D. Ziogas , H. Linardou , A. Charpidou , A. Koumarianou , G. Mountzios , P. Kosmidis , C. Christodoulou , D. Mavroudis , A.N. Christopoulou , I. Korantzis , S. Baka , M. Vaslamatzis , I. Athanasiadis , A. Koutras , D. Mauri , A. Kotsakis , A. Visvikis , F. Spanoudi , T. Tsichritzis , K. Syrigos","doi":"10.1016/j.iotech.2024.100837","DOIUrl":"10.1016/j.iotech.2024.100837","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100837"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100895
E.Y. Baitei , A. Bzura , M. Zhang , C. Poile , A. Branson , A. King , S. Barber , C. Brookes , J. Dzialo , A. Greystoke , L. Nolan , M. Dungey , M. Scotland , A. Bajaj , P. Wells-Jordan , C. Richards , A. Thomas , M.G. Krebs , D.A. Fennell
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100902
B.V. Popescu , N. Taris , A. Bendjama , L. Bender , C. Pflumio , C. Fischbach , M. Kalish-Weindling , C. Mathelin , T. Petit , X. Pivot
{"title":"19P Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab","authors":"B.V. Popescu , N. Taris , A. Bendjama , L. Bender , C. Pflumio , C. Fischbach , M. Kalish-Weindling , C. Mathelin , T. Petit , X. Pivot","doi":"10.1016/j.iotech.2024.100902","DOIUrl":"10.1016/j.iotech.2024.100902","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100902"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100740
W.K. Lim , N.G. Iyer
γδ T cells represent an ‘unconventional’ class of CD3+ lymphocytes with unique phenotypical and functional attributes that distinguishes them from their αβ T-cell receptor-expressing counterparts. Studies investigating the roles of γδ T cells in cancer have shown that these cells are indispensable for effective tumor control and their presence within the tumor may be of prognostic significance. Currently, there is significant interest in harnessing γδ T cells for cancer treatment, and research efforts have focused on the development of γδ T-cell-based strategies that are efficacious against cancer. Several therapeutic approaches using γδ T cells have been described, premised on the expansion of γδ T cells or γδ chimeric antigen receptor T therapy. The potential for broad, unbiased and ‘off-the-shelf’ applicability in cancer treatment, drives ongoing and future research and methodologies by which γδ T cells can be exploited for therapeutic use. In this review, we will briefly outline the characteristics of γδ T cells and describe how these work within and promote proper functioning of the cancer-immunity cycle. Additionally, we will introduce strategies that are less commonly described and may potentially be more efficacious than other types of therapy. Our discussion will expand upon presently known applications and even highlight the versatility of this immune subset as cancer therapeutics. γδ T-cell-based treatment is an emerging strategy and should be considered for cancelling cancer.
{"title":"A GD Type of Cancel Culture","authors":"W.K. Lim , N.G. Iyer","doi":"10.1016/j.iotech.2024.100740","DOIUrl":"10.1016/j.iotech.2024.100740","url":null,"abstract":"<div><div>γδ T cells represent an ‘unconventional’ class of CD3+ lymphocytes with unique phenotypical and functional attributes that distinguishes them from their αβ T-cell receptor-expressing counterparts. Studies investigating the roles of γδ T cells in cancer have shown that these cells are indispensable for effective tumor control and their presence within the tumor may be of prognostic significance. Currently, there is significant interest in harnessing γδ T cells for cancer treatment, and research efforts have focused on the development of γδ T-cell-based strategies that are efficacious against cancer. Several therapeutic approaches using γδ T cells have been described, premised on the expansion of γδ T cells or γδ chimeric antigen receptor T therapy. The potential for broad, unbiased and ‘off-the-shelf’ applicability in cancer treatment, drives ongoing and future research and methodologies by which γδ T cells can be exploited for therapeutic use. In this review, we will briefly outline the characteristics of γδ T cells and describe how these work within and promote proper functioning of the cancer-immunity cycle. Additionally, we will introduce strategies that are less commonly described and may potentially be more efficacious than other types of therapy. Our discussion will expand upon presently known applications and even highlight the versatility of this immune subset as cancer therapeutics. γδ T-cell-based treatment is an emerging strategy and should be considered for cancelling cancer.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100740"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.iotech.2024.100919
M. Langouo Fontsa , M. Stabile , A.C.M. Garavello , P. Delvaux , A. Goudsmit , T. Berghmans , M. Brandão , J. Blanc , M. Ilzkovitz , A.P. Meert , A. Boisson , D. Sofronii , T. Vanhulst , S. Garaud , F. Padonou , A.H. Awada , K. Willard-Gallo
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号